Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss

2007 ◽  
Vol 69 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Marco A. Costa ◽  
Manel Sabaté ◽  
Dominick J. Angiolillo ◽  
Paula Hu ◽  
Pilar Jimenez-Quevedo ◽  
...  
Keyword(s):  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Bare Metal ◽  
Luminal Diameter ◽  
Late Loss ◽  
Drug Eluting ◽  
Minimal Luminal Diameter

scholarly journals Clinical outcomes after the endovascular treatments of pulmonary vein stenosis in patients with congenital heart disease

2019 ◽  
Vol 29 (8) ◽  
pp. 1057-1065 ◽  
Author(s):  
Yoshihiko Kurita ◽  
Kenji Baba ◽  
Maiko Kondo ◽  
Takahiro Eitoku ◽  
Shingo Kasahara ◽  
...  
Keyword(s):  
Pulmonary Vein ◽  
Stent Implantation ◽  
Bare Metal Stent ◽  
Pulmonary Vein Stenosis ◽  
Drug Eluting Stent ◽  
Bare Metal ◽  
Metal Stent ◽  
Significant Difference ◽  
Drug Eluting ◽  
Vein Stenosis

AbstractBackground:Pulmonary vein stenosis (PVS) is a condition with challenging treatment and leads to severe cardiac failure and pulmonary hypertension. Despite aggressive surgical or catheter-based intervention, the prognosis of PVS is unsatisfactory. This study aimed to assess the prognosis and to establish appropriate treatment strategies.Methods:We retrospectively reviewed endovascular treatments for PVS (2001–2017) from the clinical database at the Okayama University Hospital.Results:A total of 24 patients underwent PVS associated with total anomalous pulmonary venous connection and 7 patients underwent isolated congenital PVS. In total, 53 stenotic pulmonary veins were subjected to endovascular treatments; 40 of them were stented by hybrid (29) and percutaneous procedures (11) (bare-metal stent, n = 34; drug-eluting stent, n = 9). Stent size of hybrid stenting was larger than percutaneous stenting. Median follow-up duration from the onset of PVS was 24 months (4–134 months). Survival rate was 71 and 49% at 1 and 5 years, respectively. There was no statistically significant difference between stent placement and survival; however, patients who underwent bare-metal stent implantation had statistically better survival than those who underwent drug-eluting stent implantation or balloon angioplasty. Early onset of stenosis, timing of stenting, and small vessel diameter of pulmonary vein before stenting were considered as risk factors for in-stent restenosis. Freedom from re-intervention was 50 and 26% at 1 and 2 years.Conclusions:To improve survival and stent patency, implantation of large stent is important. However, re-intervention after stenting is also significant to obtain good outcome.

Abstract 2955: Increased Luminal Diameter With Drug-eluting Versus Bare-metal Stenting Of The Piglet Ductus Arteriosus

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Kyong-Jin Lee ◽  
Aleksander Hinek ◽  
Claudia Almeida ◽  
Rajiv Chaturvedi ◽  
Lee Benson
Keyword(s):  
Stent Implantation ◽  
Cellular Proliferation ◽  
Ductus Arteriosus ◽  
Metal Stents ◽  
Type I ◽  
External Diameter ◽  
Bare Metal ◽  
Luminal Diameter ◽  
Extracellular Matrix Components ◽  
Drug Eluting

Introduction: Maintaining ductus arteriosus (DA) patency by stent implantation may be advantageous in congenital heart disease management algorithms. Rapamycin, an immuno-suppressant drug, has anti-proliferative properties, inhibits smooth muscle cell (SMC) migration and may deter intimal hyperplasia occurring during spontaneous closure and post stent implantation of the DA. Methods: 16 Yorkshire piglets (age 7–11 days old, weight 2.2– 4.9 kg) underwent stent implantation of the DA (rapamycin-eluting (n = 8), bare metal (n = 8) stents, (3.5 mm diameter) and were sacrificed at 2, 4 and 6 weeks. Dissected DA were analyzed for SMC and extracellular matrix components (elastin, collagen and glycosaminoglycans). External diameter, wall thickness and lumen diameter were analyzed by morphometric software. DA-derived SMC were isolated and cultured for 7 days in the presence or absence of 100mM of rapamycin. Cellular proliferation rates were assessed by proliferative antigen Ki-67 detection and [ 3 H]-thymidine incorporation. Specific antibodies to elastin, collagen type I, and chondroitin sulfate-containing glycosaminoglycans were analyzed. Results: Rapamycin-eluting stents significantly inhibited neointimal formation compared with bare metal stents at 4 and 6 weeks resulting in larger luminal diameters (p<0.001). The in vitro studies demonstrated rapamycin-treated cultures of the DA-derived SMC had 50% lower proliferation rates (p<0.001). Conclusions : Rapamycin has anti-proliferative actions on the DA. Drug-eluting stents may be a more efficient tool for prolonging patency of the DA in neonates palliated for future correctional surgery.

Sign in / Sign up

Export Citation Format

Share Document